Brain Glioma Treatment
Brain Glioma Treatment
Treatment for a glioma is a sequence in which each step depends on the results of the last. The operation has two purposes — to remove as much of the tumour as can be removed safely, and to provide the tissue that defines the diagnosis. The molecular results then decide what follows: which tumours need radiotherapy and chemotherapy straight away, which are monitored, and which are treated with a targeted drug instead. Because the tumour infiltrates tissue that cannot be removed, the aim throughout is control and function rather than a single definitive procedure.
The operation
Surgery is the first treatment for almost every glioma, and its two purposes are equally important:
- Removal as complete as is safe — described as the maximal safe resection, because the limit is not the tumour but the function of the tissue around it. The extent achieved is judged on the scan taken after the operation.
- Providing the tissue diagnosis — the specimen is what the neuropathologist and the molecular laboratory work from, and a larger specimen gives more certainty about the grade.
- Relieving pressure — removing tumour reduces the pressure inside the skull, which is why many symptoms improve within days of the operation.
- Awake craniotomy when function is at stake — the patient is woken during the operation and asked to speak or move so that the surgeon can identify and avoid the areas responsible. It sounds daunting and is generally tolerated well, and it is the most reliable way to protect speech and movement.
- Techniques that extend what is possible — intraoperative imaging, ultrasound and fluorescence guidance help judge the tumour boundary during the operation, and neurophysiological monitoring tracks nerve function continuously.
- A second operation is sometimes the right choice, either to remove more tumour than was safe at the first attempt, or later if the tumour recurs in a resectable site.
Radiotherapy
Radiotherapy is given after surgery to the tissue around the tumour, because infiltration extends beyond what the scan shows and beyond what the surgeon can see:
- It is given as a fractionated course — a small dose each weekday over several weeks, which allows normal tissue to recover between treatments while the tumour does not.
- The target is defined from imaging, including the region of abnormal tissue and a margin around it, with the dose plan designed to limit what the surrounding brain receives.
- It is not given immediately to every tumour. For a completely removed grade 1 tumour, or for selected slow-growing tumours in patients who are well, monitoring may be the better first step and radiotherapy can be held in reserve.
- Re-irradiation is an option in selected recurrences, decided on the basis of the time since the first course, the site and what the surrounding tissue has already received.
- The side effects are largely manageable — fatigue during the course, hair loss over the treated area, and sometimes temporary worsening of symptoms from swelling, which is treated with steroids. Long-term effects relate to the dose and the volume treated, which is why the plan is shaped so carefully.
Chemotherapy
Chemotherapy for glioma is chosen by molecular type rather than applied uniformly, and the reason is that the types differ in how they respond:
- Temozolomide during and after radiotherapy — the standard for glioblastoma and for IDH-mutant astrocytoma. It is taken as a tablet, which means most of the course is given at home with blood tests to monitor the counts.
- MGMT promoter methylation is the result that predicts who benefits most, and it is reported before the decision is made — which is why the molecular panel is not a formality.
- The PCV combination — procarbazine, lomustine and vincristine — or temozolomide for oligodendroglioma with the 1p/19q codeletion, a type in which chemotherapy contributes substantially and is given alongside radiotherapy rather than only at recurrence.
- Lomustine and other agents at recurrence, either alone or with a further drug, chosen according to what has already been given and how long the interval has been.
- The blood count is the main thing monitored, because these drugs suppress the marrow; the dose is adjusted rather than abandoned when the counts fall.
Targeted treatment and tumour treating fields
Two further approaches have a defined place, and both depend on the tumour's molecular profile rather than on its size or site:
- An oral IDH inhibitor — available for selected patients with a slower-growing IDH-mutant glioma, taken as a tablet and monitored with imaging. It is a treatment option for a defined group rather than for all gliomas, which is why the IDH result matters twice over.
- Tumour treating fields — delivered through arrays worn on the scalp that produce low-intensity alternating fields across the tumour. They are used after radiotherapy in glioblastoma, are worn for most of the day, and are offered as an addition rather than as a replacement.
- BRAF-directed treatment in tumours carrying a BRAF alteration, including some circumscribed gliomas of childhood and young adults, where a targeted drug may be used instead of conventional chemotherapy.
- Bevacizumab — an antibody that reduces the swelling around a tumour. Its main role is controlling symptoms in recurrent disease rather than changing the course of the tumour itself, and it is used with that expectation stated.
- Clinical trials — a reasonable option at any stage for patients who are eligible, and particularly relevant in a disease where the molecular profile increasingly determines which drug is worth trying.
When the tumour returns
Most diffuse gliomas eventually grow again, and the decision at that point is about which treatment suits the situation rather than about a standard next step:
- Distinguishing true progression from treatment effect — imaging changes after radiotherapy can reflect treatment effect rather than tumour growth, and the distinction is made with perfusion imaging, spectroscopy or a short interval of repeat scanning rather than by assuming the worst.
- Further surgery where the recurrence is in a site that can be operated on, which both reduces the tumour and provides tissue to confirm what has changed.
- Re-irradiation in selected cases, decided by the interval since the first course and by what the surrounding tissue can tolerate.
- A change of drug treatment — lomustine, a further course of temozolomide if the interval has been long, bevacizumab for swelling, or a targeted agent where the molecular profile supports one.
- Re-examining the molecular profile at recurrence is increasingly worthwhile, because a tumour can acquire new findings over time that open a treatment that was not previously relevant.
- The written history becomes decisive — what was removed and when, the molecular results at diagnosis, the radiotherapy dose and target, and the drugs given with their dates. That record determines what is sensible next.
Supportive treatment and rehabilitation
In glioma, supportive treatment is not ancillary. It protects function, which is what the treatment is for:
- Steroids for swelling — used at the lowest dose and for the shortest time that works, because they cause weight gain, raised blood sugar, mood change, muscle weakness and a risk of infection. Improvement on steroids is welcome but is not a measure of the tumour.
- Anti-epileptic medication when seizures have occurred, with the aim of controlling them at the lowest effective dose. It is not given routinely to patients who have never had a seizure.
- Clot prevention during and after surgery, and in patients whose mobility is reduced, because the risk of a clot is higher in this group.
- Physiotherapy, speech and language therapy, and cognitive support — arranged from the start, because gains are greatest in the weeks after an operation and because function, not imaging alone, is what determines daily life.
- Treatment for raised pressure — including a shunt or a drainage procedure in the minority of patients in whom the fluid spaces become blocked.
- Driving and safety advice, which follows the seizure situation and local rules, and is a concrete question worth asking early rather than assuming.
- Mood and psychological support, for the patient and for the family, since the diagnosis and the changes it brings are both treated rather than endured.
How the plan is made and reviewed
Glioma treatment is decided by a group rather than by one specialty, because the sequence crosses several disciplines and each decision constrains the next:
- Neurosurgery leads the operation and judges what could be removed safely.
- Neuropathology reports the tumour type, the grade and the molecular panel on which everything else is based.
- Radiation oncology plans the target and the dose, and decides whether and when radiotherapy should be given.
- Neuro-oncology chooses and sequences the drug treatment and coordinates the monitoring.
- Neuroradiology reports the imaging, distinguishes treatment effect from progression, and guides any biopsy.
- Neurorehabilitation and neuropsychology assess and restore function, and record what has changed objectively.
- The output should be a written sequence with decision points — what is done now, which result decides the next step, and when the next scan is due. In a disease treated over years with several possible paths, that document is what allows care to continue coherently, including from another country.